ReNetX Bio
New Haven
About ReNetX Bio
ReNetX Bio first-in-class therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI)and glaucoma.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $9.8M
- Last round: Series Unknown (Sep 2020)
- Website: renetx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Information Technology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/renetx-bio-84722 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.